CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 26 pages
Pedro L. Moro, MD, MPH Division of Healthcare Quality Promotion Centers for Disease Control and Prevention (CDC)NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES Maternal RSV vaccine safety surveillance Advisory Committee on Immunization Practices (ACIP) June 28, 2024 ▪The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the CDC ▪The use of product trade names is for identification purposes…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 32 pages
Summary of effectiveness of nirsevimab in infants Amanda Payne, PhD, MPH Coronavirus and Other Respiratory Viruses Division Centers for Disease Control and Prevention June 28, 2024National Center for Immunization and Respiratory Diseases •Real -world vaccine/product effectiveness methods •Effectiveness of nirsevimab in the United States -RSV-associated emergency department encounters & hospitalization, VISION -RSV-associated medical encounters and hospitalization, NVSN •Effectiveness of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 20 pages
Maternal/Pediatric RSV Work Group Considerations CDR Jefferson Jones, MD MPH FAAP, USPHS Co-lead, Respiratory Syncytial Virus Vaccines – Maternal/Pediatric Work Group Coronavirus and Other Respiratory Viruses Division ACIP General Meeting June 28, 2024National Center for Immunization and Respiratory Diseases •Anticipated supply of maternal RSV vaccine and nirsevimab •Updates on post -introduction nirsevimab and maternal RSV vaccine safety and effectiveness monitoring •Revaccination of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 10 pages
Introduction to the HPV Vaccines Work Group Oliver Brooks, MD Chair, HPV Vaccine Work Group Advisory Committee on Immunization Practices June 28, 2024 National Center for Immunization & Respiratory Diseases 2006 2011 2016 2019 Recommendation for Females Routine : 11 or 12 years , can be started at age 9 Catch -up: through 26 years 3-dose scheduleEvolution of HPV vaccination recommendations – United States 2Recommendation for Males Routine : 11 or 12 years , can be…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. ACIP COVID- 19 Vaccines Work Group Dr. Matthew F. Daley, Work Group Chair February 28, 2024 ACIP met September 12, 2023 to review the available evidence for updated…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 13 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. COVID- 19–Associated Hospitalizations among Adults — COVID- NET, 2023 –2024 Advisory Committee on Immunization Practices (ACIP) February 28, 2024 Christopher A. Taylor,…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 27 pages
National Center for Immunization & Respiratory Diseases An update on COVID- 19 vaccination coverage CDR Kevin Chatham -Stephens, MD, MPH, FAAP Readiness and Response Lead Immunization Services DivisionNational Center for Immunizations and Respiratory Diseases (NCIRD) COVID -19 vaccination coverage Percent of adults and children up- to-date with 2023– 24 COVID -19 Vaccine National Immunization Survey -Adult COVID Module (NIS -ACM) and - Child COVID Module (NIS -CCM) 0.010.020.030.040.050.0…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 21 pages
1 Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Vaccine effectiveness of updated (2023 -2024) COVID -19 vaccines February 2024 Ruth Link- Gelles, PhD, MPH CDR, US Public Health Service Vaccine Effectiveness Program…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 24 pages
Economic analysis of an additional dose of COVID -19 vaccine University of Michigan COVID -19 Vaccination Modeling Team Model updates & additional analysis February 2024 1 Study team University of Michigan •Lisa A. Prosser, PhD, Principal Investigator •David W. Hutton, PhD, Co -Investigator •Acham Gebremariam, MS, Programmer/Analyst •Angela Rose, MS, MPH, Project Manager •Kerra Mercon, MS, Research Assistant Wake Forest University •Cara Janusz, PhD Additional contributors to 2021 Covid…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 81 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Evidence to Recommendations Framework: Additional Dose of 2023-2024 Formula COVID -19 Vaccine in Older Adults Megan Wallace, DrPH, MPH ACIP Meeting February 28, 2024…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Next Steps for the COVID- 19 Vaccine Program Lakshmi Panagiotakopoulos, MD, MPH ACIP MeetingFebruary 28, 2024 Can we improve the current COVID- 19 vaccine policy…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
CHIKUNGUNYA VACCINES Wilbur Chen, MD, MS Chair, ACIP Chikungunya Vaccines Work GroupACIP Meeting February 28, 2024 Background Chikungunya vaccine (manufactured by Valneva) was licensed in the United States in November 2023 No other chikungunya vaccine licensed globally No existing ACIP chikungunya vaccine recommendations Chikungunya Vaccines Work Group is developing policy options for ACIP’s consideration for use of chikungunya vaccine among U.S. persons at risk of chikungunya, including…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
National Center for Emerging and Zoonotic Infectious Diseases UPDATE ON LICENSURE OF LIVE ATTENUATED CHIKUNGUNYA VACCINE Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, February 28, 2024 Key points from FDA licensure and package insert Vaccine approved on November 9, 2023 and named IXCHIQ Indicated for individuals at increased risk of exposure to chikungunya virus Single…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 28 pages
National Center for Emerging and Zoonotic Infectious Diseases PROPOSED POLICY OPTIONS FOR CHIKUNGUNYA VACCINE USE AMONG U.S. ADULT TRAVELERS Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, February 28, 2024 Chikungunya virus and transmission Alphavirus Key vectors are Aedes aegypti and Aedes albopictus mosquitoes Mainly feed in daytime with peak activity early morning…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 7 pages
National Center for Emerging and Zoonotic Infectious Diseases PROPOSED POLICY OPTIONS FOR CHIKUNGUNYA VACCINE USE AMONG U.S. LABORATORY WORKERS Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, February 28, 2024 Chikungunya virus infections among laboratory workers At least 44 infections identified among laboratory workers worldwide over ~ 50 years1–3 –43 cases overt…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 28 pages
National Center for Emerging and Zoonotic Infectious Diseases CLINICAL GUIDANCE FOR USE OF LIVE ATTENUATED CHIKUNGUNYA VACCINE AMONG PREGNANT AND BREASTFEEDING INDIVIDUALS Susan Hills, MBBS, MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP meeting, February 28, 2024 Clinical guidance for use of live attenuated chikungunya vaccine in pregnant individuals Presentation of chikungunya among pregnant…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 19 pages
National Center for Immunization & Respiratory Diseases VFC Resolution Update: Tetanus and Diphtheria Toxoid Containing Vaccines Michelle Hughes Division of Bacterial Diseases National Center for Immunization and Respiratory DiseasesJeanne Santoli Immunization Services Division National Center for Immunization and Respiratory Diseases February 2024 Background Background •CDC recommends a primary series of 5 DTaP vaccines for children <7 years •For children aged <7 years who developed a…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 37 pages
National Center for Immunization & Respiratory Diseases Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness Aaron M. Frutos, PhD, MPH On behalf of CDC Influenza Vaccine Effectiveness Collaborators Advisory Committee on Immunization Practices February 28, 2024 CDC Influenza Vaccine Effectiveness Networks Four networks to evaluate vaccine effectiveness (VE) against laboratory - confirmed influenza for children, adolescents, and adults in the outpatient and inpatient settings …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 15 pages
1Sophie Zhu, PhD, presenting on behalf of the study team Epidemic Intelligence Service Officer California Department of Public Health Influenza VEData: Interviews, electronic health records New: California public health dataMultiple considerations for vaccine effectiveness (VE) calculation Populations: Pediatric, hospitalizedCare settings 2 New requirements for data reporting in California •1/1/23: Influenza vaccination records became reportable to the California Immunization Registry…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 18 pages
Safety of Live Attenuated Influenza Vaccine in Children with Asthma C. Buddy Creech, MD, MPH Edie Carell Johnson Chair and Professor, Pediatric Infectious Diseases Director, Vanderbilt Vaccine Research Program Vanderbilt University Medical Center Nashville, Tennessee Advisory Committee on Immunization Practices (ACIP) Meeting February 28, 2024 Disclaimer •The findings and conclusions in this presentation are those of the presenter and do not necessarily represent the official position of…